Last reviewed · How we verify
NCT06996262
Cardiometabolic Risk Factors and Processed Food
trial testing observational study in Cardiac Disease in 236 participants. Completed in 30 April 2024.
30 April 2024
Quick facts
| Lead sponsor | Istanbul Bilgi University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 236 |
| Start date | 1 March 2024 |
| Primary completion | 30 April 2024 |
| Estimated completion | 30 April 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- observational study — full drug profile →
- observational study — full drug profile →
- observational study — full drug profile →
- observational study — full drug profile →
Conditions studied
- Cardiac Disease — all drugs for Cardiac Disease →
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
- Nutrition — all drugs for Nutrition →
- Nutritional Disease — all drugs for Nutritional Disease →
Sponsor
Istanbul Bilgi University
Who can join
Adults 18 to 65, any sex, with Cardiac Disease or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cardiovascular diseases (CVD) remain a primary cause of chronic disability and mortality globally, with cardiometabolic risk factors such as hypertension, dyslipidemia, obesity, and diabetes significantly contributing to their development. Poor nutrition is recognized as a modifiable key risk factor for CVD, representing a crucial area for prevention strategies. While current research often emphasizes overall dietary patterns and quality in CVD prevention, the spectrum of food processing, ranging from minimally processed to ultra-processed foods (UPFs), can profoundly influence diet quality. Ultra-processed foods, characterized by industrial processing techniques, additives, and special industrial ingredients, have been shown to potentially compromise the health benefits of food by reducing essential nutrients and bioactive compounds, introducing unhealthy elements, and altering food structures. Emerging epidemiological evidence links higher UPF consumption to an increased risk of obesity, hypertension, metabolic syndrome, and type 2 diabetes, with studies like the Framingham Offspring Study indicating a positive association with CVD incidence. Globally, UPF consumption is on the rise, constituting a significant portion of daily energy intake. In Turkey, data from the 2021 National Nutrition and Health Survey reveals that a substantial 58% of adults consume processed foods daily . This is particularly concerning given Turkey's high burden of CVD, which has been the leading cause of mortality for decades and is projected to increase further due to an aging population and rising rates of diabetes and obesity. Notably, Turkey has the highest rate of early myocardial infarction in Europe. Given the increasing consumption of UPFs and their potential health implications, especially in a country with a high prevalence of CVD like Turkey, understanding the relationship between dietary factors and cardiovascular health is critical. Therefore, this study aims to investigate the association between processed food intake and cardiometabolic risk factors among adult individuals in Türkiye.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Processed Food Consumption Based on the NOVA Classification Is Associated With Elevated Cardiometabolic Risk in Turkish Adults.
Ozkan I, Ozlu Karahan T, Seven Avuk H. · · 2025 · PMID 41019184 · DOI 10.1002/fsn3.71014
Verify or expand the search:
- PubMed search for NCT06996262
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of observational study
Trials testing the same drug.
- NCT07497139 — Sepsis Induced Myocardial Injury in Critically Ill Children · not yet recruiting
- NCT07379567 — BREVOC Study: Exhaled VOCs for High-Risk Chest Pain in the ED · not yet recruiting
- NCT07391007 — Integrated Clinical-molecular Risk Stratification to Early Recurrence in Colorectal Liver Metastases · not yet recruiting
- NCT07372183 — Wound Healing Following Extraction and Ridge Preservation in Smokers and Non-smokers · not yet recruiting
- NCT07310186 — Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy · not yet recruiting
Other recruiting trials for Cardiac Disease
Currently open trials in the same condition.
- NCT07532174 — Efferon LPS Hemoadsorption in Cardiac Surgery Patients · NA · recruiting
- NCT06294119 — Multivariate Approach to the Numerical Assessment of Cortical - Autonomic - VAscular Dynamic Interplay · NA · recruiting
- NCT07274436 — The Clinical Value of Deep Learning-Based Reconstruction Techniques in Cardiac MRI Scanning · recruiting
- NCT07217392 — Left Bundle Branch Area Pacing (LBBAP) PMCF Study · NA · recruiting
- NCT05877755 — Validation of Multi-contrast, High-resolution Cardiac Magnetic Resonance Imaging · NA · recruiting
Other Istanbul Bilgi University trials
Trials by the same sponsor.
- NCT06800144 — Effect of Music Therapy on Pain in People With Multiple Sclerosis · NA · recruiting
- NCT06847763 — The Long Term Effects of Online Therapeutic Neuroscience Education in Patients With Chronic Low Back Pain · NA · recruiting
- NCT07293624 — Effects of the Dietary Inflammatory Index on Systemic Inflammation Markers and Gastrointestinal Symptoms in Individuals · enrolling by invitation
- NCT07004478 — Turkish Adaptation Study of the Generic Functional Index · recruiting
- NCT07114341 — Effect of Lyophilized Cornelian Cherry on Anaerobic Performance in Young Football Players · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06996262 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istanbul Bilgi University
- Last refreshed: 30 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06996262.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing